Raymond James Financial’s VanEck Biotech ETF BBH Stock Holding History

Raymond James Financial’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.1M	Sell	69,560 -2,451	-3%	-$472K	﹤0.01%	1799
2025 Q4	$13.6M	Buy	72,011 +2,202	+3%	+$407K	﹤0.01%	1725
2025 Q3	$11.6M	Buy	69,809 +1,869	+3%	+$305K	﹤0.01%	1801
2025 Q2	$10.4M	Buy	67,940 +48,297	+246%	+$7.19M	﹤0.01%	1835
2025 Q1	$3.09M	Sell	19,643 -1,896	-9%	-$308K	﹤0.01%	2676
2024 Q4	$3.38M	Buy	+21,539	New	+$3.62M	﹤0.01%	2585

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

PPWM

Paragon Private Wealth Management Lexington, Kentucky $383M AUM 36.18% 1-Year Est. Return

Raymond James Financial's BBH Position: Q1 2026 in Review

Raymond James Financial reduced its VanEck Biotech ETF (BBH) stake by 3.4% in Q1 2026, selling an estimated $472K and leaving 69,560 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1799.

Raymond James Financial first reported a position in BBH in Q4 2024 and has held it in 6 quarters since. The position peaked at $13.6M in Q4 2025. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

Raymond James Financial held 69,560 shares of VanEck Biotech ETF worth $13.1M as of Q1 2026.
Raymond James Financial sold 2,451 VanEck Biotech ETF shares in Q1 2026, an estimated $472K.
VanEck Biotech ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #1799 holding.
Raymond James Financial first reported a position in VanEck Biotech ETF in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's VanEck Biotech ETF position peaked at $13.6M in Q4 2025.
112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.